Because HD-TOR is less expensive than other endocrine therapies with inhibitors of growth signaling pathways (Table 4), HD-TOR is a suitable candidate for breast cancer patients with secondary resistance to AIs. This evidence concerns the gene RORC and breast carcinoma.